Open Orphan subsidiary signs £3m contract for Covid-19 study

 
Dublin-listed pharmaceutical services company Open Orphan has announced that its subsidiary hVivo has signed a £3 million contract to develop a “challenge virus” based on new emerging variants of Covid-19.
The contract is with Imperial College London as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.
Under the agreement, hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants of the virus, which will be used in future hVivo-run human challenge trials to allow direct comparisons of vaccines or antivirals against different Covid-19 variants.
In virus challenge studies, healthy volunteers are administered a pathogenic or virulent strain of virus.

Related Keywords

Wuhan ,Hubei ,China ,Dublin ,Ireland ,London ,City Of ,United Kingdom ,Chris Chiu ,Andrew Catchpole ,Imperial College London ,Wellcome ,Wellcome Trust ,Respiratory Syncytial Virus ,சீனா ,டப்ளின் ,ஐயர்ல்யாஂட் ,லண்டன் ,நகரம் ஆஃப் ,ஒன்றுபட்டது கிஂக்டம் ,கிறிஸ் சியு ,ஆண்ட்ரூ கேட்ச்போல் ,ஏகாதிபத்தியம் கல்லூரி லண்டன் ,வெல்கம் ,வெல்கம் நம்பிக்கை ,